Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
L-2-hydroxyglutaric aciduria is a primarily neurological form of 2-hydroxyglutaric aciduria characterized by psychomotor retardation, cerebellar ataxia and variable macrocephaly or epilepsy.
Features include always present findings: Seizure, Leukoencephalopathy, Ataxia, and L-2-hydroxyglutaric aciduria and others. 21 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 11 | Loss of previously acquired skills (developmental regression), Seizure, Leukoencephalopathy |
L2HGDH encodes L-2-hydroxyglutarate dehydrogenase (463 aa). Highest expression in Cells EBV-transformed lymphocytes (8.6 TPM) and Brain Cerebellar Hemisphere (8.3 TPM).
L-2-hydroxyglutaric aciduria is associated with mutations in the L2HGDH gene on chromosome 14.
The L2HGDH protein participates in Interconversion of 2-oxoglutarate and 2-hydroxyglutarate pathway.
L2HGDH is classified as a druggable target (Enzyme category) with score 0.0.
Genetic testing for L2HGDH is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for L-2-hydroxyglutaric aciduria has been reported in the published literature.
Phenotype severity distribution: 5 always present features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE1. Research is primarily sponsored by academic and government institutions.
16 publications have been identified in PubMed for L-2-hydroxyglutaric aciduria. Research spans Case Report / Case Series (56%), Basic Science / Preclinical (19%), and Diagnostic / Biomarker (6%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 9 | 56% |
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 6:43 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about L-2-hydroxyglutaric aciduria
Muscles
4 |
Shrinkage of the cerebellum (cerebellar atrophy), Global brain atrophy, Corpus callosum atrophy |
Eyes | 3 | Strabismus, Nystagmus, Damage to the optic nerve (optic atrophy) |
Ears | 1 | Hearing loss (hearing impairment) |
Laboratory research |
3 |
19% |
Testing and diagnosis research | 1 | 6% |
Research summaries | 1 | 6% |
Disease patterns and progression | 1 | 6% |
New treatment approaches | 1 | 6% |
Bıyık MO (2026). [PMID: 41936723](https://pubmed.ncbi.nlm.nih.gov/41936723/). *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. [Review / Meta-Analysis]
Finsterer J (2026). [PMID: 42205672](https://pubmed.ncbi.nlm.nih.gov/42205672/). *Cureus*. [Case Report / Case Series]
Chakrabarty RP (2026). [PMID: 42162436](https://pubmed.ncbi.nlm.nih.gov/42162436/). *Nature*. [Basic Science / Preclinical]
Radhakrishnan DM (2025). [PMID: 40462650](https://pubmed.ncbi.nlm.nih.gov/40462650/). *Movement disorders clinical practice*. [Case Report / Case Series]
Engin Erdal A (2025). [PMID: 40660807](https://pubmed.ncbi.nlm.nih.gov/40660807/). *Journal of pediatric endocrinology & metabolism : JPEM*. [Diagnostic / Biomarker]
Lipiński P (2025). [PMID: 40380983](https://pubmed.ncbi.nlm.nih.gov/40380983/). *Journal of applied genetics*. [Case Report / Case Series]
Kasprzyk-Pawelec A (2025). [PMID: 39733217](https://pubmed.ncbi.nlm.nih.gov/39733217/). *Cell death and differentiation*. [Gene Therapy / Novel Therapeutics]
Shimozato M (2025). [PMID: 39880652](https://pubmed.ncbi.nlm.nih.gov/39880652/). *Rinsho shinkeigaku = Clinical neurology*. [Case Report / Case Series]
Guo Q (2025). [PMID: 40870031](https://pubmed.ncbi.nlm.nih.gov/40870031/). *Genes*. [Case Report / Case Series]
Phua YL (2024). [PMID: 38772223](https://pubmed.ncbi.nlm.nih.gov/38772223/). *Molecular genetics and metabolism*. [Basic Science / Preclinical]